Integer Holdings Co. (NYSE:ITGR) Receives Consensus Rating of "Moderate Buy" from Analysts

Integer Holdings Co. (NYSE:ITGR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine analysts that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $147.67.

Several equities analysts have weighed in on ITGR shares. Benchmark raised their price target on Integer from $140.00 to $150.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Truist Financial lifted their price objective on Integer from $147.00 to $163.00 and gave the company a "buy" rating in a research report on Wednesday, December 11th. Wells Fargo & Company reaffirmed an "overweight" rating and issued a $160.00 price objective on shares of Integer in a research report on Tuesday, December 3rd. Citigroup lifted their price objective on Integer from $130.00 to $145.00 and gave the company a "neutral" rating in a research report on Wednesday, December 11th. Finally, KeyCorp lifted their price objective on Integer from $144.00 to $154.00 and gave the company an "overweight" rating in a research report on Friday, January 24th.

Institutional Investors Weigh In On Integer

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Capital Research Global Investors boosted its position in shares of Integer by 16.0% in the fourth quarter. Capital Research Global Investors now owns 1,410,803 shares of the medical equipment provider's stock worth $186,960,000 after buying an additional 194,895 shares during the period. Geode Capital Management LLC boosted its position in shares of Integer by 1.2% in the third quarter. Geode Capital Management LLC now owns 764,528 shares of the medical equipment provider's stock worth $99,408,000 after buying an additional 9,421 shares during the period. Loomis Sayles & Co. L P boosted its position in shares of Integer by 3.8% in the fourth quarter. Loomis Sayles & Co. L P now owns 558,715 shares of the medical equipment provider's stock worth $74,041,000 after buying an additional 20,688 shares during the period. Congress Asset Management Co. boosted its position in shares of Integer by 2.0% in the fourth quarter. Congress Asset Management Co. now owns 498,350 shares of the medical equipment provider's stock worth $66,041,000 after buying an additional 9,565 shares during the period. Finally, Driehaus Capital Management LLC boosted its position in shares of Integer by 5.5% in the fourth quarter. Driehaus Capital Management LLC now owns 451,464 shares of the medical equipment provider's stock worth $59,828,000 after buying an additional 23,706 shares during the period. 99.29% of the stock is currently owned by institutional investors and hedge funds.

Integer Stock Performance

Integer stock opened at $120.08 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.09 and a current ratio of 2.95. The stock has a fifty day moving average of $134.96 and a two-hundred day moving average of $132.94. The company has a market capitalization of $4.04 billion, a price-to-earnings ratio of 35.74, a PEG ratio of 1.72 and a beta of 1.24. Integer has a fifty-two week low of $107.11 and a fifty-two week high of $146.36.

Remove Ads

Integer (NYSE:ITGR - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing the consensus estimate of $1.46 by ($0.03). The company had revenue of $449.50 million for the quarter, compared to analysts' expectations of $446.28 million. Integer had a return on equity of 11.65% and a net margin of 6.92%. On average, analysts anticipate that Integer will post 6.01 EPS for the current fiscal year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.